OTC$SMNR
Semnur Pharmaceuticals Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
SMNR Q1 2024 — $50.0M revenue
The Company is currently not aware of any issues under review that could result. Semnur Pharmaceuticals Inc reported Q1 2024 results. Net income of $1.0M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $50.0M.
- Net income: $1.0M.
- Filed on Form 10-Q (accession 0001213900-24-045702).
Headline financials
Revenue & EPS history
Denali Capital Acquisition-A · Revenue · Quarterly
$50M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
+0.2%
Avg return
Earnings day
—
Avg return
5 days after
—
Avg return
30 days after
63%
5 / 8 earnings
Positive
+8.5%
Q4 2023
Best reaction
-8.0%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | — | — | — | |
| Q3 2024 | -0.8% | — | — | |
| Q2 2024 | +1.6% | — | — | |
| Q1 2024 | -8.0% | — | — | |
| Q4 2023 | +8.5% | — | — | |
| Q3 2023 | +0.1% | — | — | |
| Q2 2023 | +0.2% | — | — | |
| Q1 2023 | +0.0% | — | — | |
| Q4 2022 | +0.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro